Jérôme Tamburini

13.9k total citations
88 papers, 3.3k citations indexed

About

Jérôme Tamburini is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Jérôme Tamburini has authored 88 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 46 papers in Molecular Biology and 22 papers in Genetics. Recurrent topics in Jérôme Tamburini's work include Acute Myeloid Leukemia Research (31 papers), PI3K/AKT/mTOR signaling in cancer (17 papers) and Multiple Myeloma Research and Treatments (14 papers). Jérôme Tamburini is often cited by papers focused on Acute Myeloid Leukemia Research (31 papers), PI3K/AKT/mTOR signaling in cancer (17 papers) and Multiple Myeloma Research and Treatments (14 papers). Jérôme Tamburini collaborates with scholars based in France, Switzerland and United States. Jérôme Tamburini's co-authors include Didier Bouscary, Nicolas Chapuis, Patrick Mayeux, Lise Willems, Valérie Bardet, Alexa S. Green, Catherine Lacombe, Sophie Park, Norbert Ifrah and François Dreyfus and has published in prestigious journals such as Blood, American Journal of Respiratory and Critical Care Medicine and Clinical Cancer Research.

In The Last Decade

Jérôme Tamburini

85 papers receiving 3.2k citations

Peers

Countries citing papers authored by Jérôme Tamburini

Since Specialization

Citations

This map shows the geographic impact of Jérôme Tamburini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Tamburini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Tamburini more than expected).

Fields of papers citing papers by Jérôme Tamburini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Tamburini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Tamburini. The network helps show where Jérôme Tamburini may publish in the future.

Co-authorship network of co-authors of Jérôme Tamburini

This figure shows the co-authorship network connecting the top 25 collaborators of Jérôme Tamburini. A scholar is included among the top collaborators of Jérôme Tamburini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérôme Tamburini. Jérôme Tamburini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐cell lymphoma: Insights from real‐life clinical practice 2024 ·Cancer Reports ·(unknown), (unknown), Thomas McKee, Nicolas Mach, Kaveh Samii, Martine E.D. Chamuleau, Frank Stenner, Jérôme Tamburini, (unknown)	1
2	Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study 2024 ·The Lancet Haematology ·(unknown), (unknown), Justine Decroocq, Laurent Chouchana, (unknown), (unknown), Vassilis Tsatsaris, (unknown), Jérémie Zerbit, Barbara Burroni, Frédéric Pène, (unknown), Caroline Charlier, Jérôme Tamburini, Nathanaël Beeker, (unknown), Didier Bouscary, Jean‐Marc Tréluyer, Rudy Birsen	2
3	The E3 ubiquitin ligase MARCH5 promotes mitochondrial fusion and cell-cycle progression in acute myeloid leukemia 2024 ·Blood Advances ·Clément Larrue, Sarah Mouche, Jérôme Tamburini	1
4	Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA 2023 ·British Journal of Haematology ·(unknown), Nicolas Molinari, David Sibon, Anne‐Ségolène Cottereau, Salim Kanoun, C. Antoine, (unknown), Doriane Cavalieri, Luc‐Matthieu Fornecker, Olivier Casasnovas, Charles Herbaux, (unknown), Cédric Rossi, Didier Bouscary, Pauline Brice, Hervé Ghesquières, Jérôme Tamburini, Bénédicte Deau	0
5	Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin 2020 ·Bone Marrow Transplantation ·(unknown), (unknown), Emmanuelle Tavernier, (unknown), Frédérique Kuhnowski, Jérôme Tamburini, Luc‐Matthieu Fornecker, Vincent Camus, David Sibon, Marie‐Pierre Moles, Sylvie Glaisner, (unknown), Sebastien Mulé, Julien Caldéraro, Daniel Azoulay, Jehane Fadlallah, Corinne Haïoun, Jehan Dupuis	3
6	Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study 2019 ·British Journal of Haematology ·Johanna Mondésir, (unknown), David Sibon, Lise Willems, Bénédicte Deau, Felipe Suárez, Olivier Hermine, Michaëla Fontenay, Didier Bouscary, Olivier Kosmider, Jérôme Tamburini	1
7	Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study 2018 ·British Journal of Haematology ·Bénédicte Deau, Sandy Amorim, Aurore Perrot, Philippe Quittet, Jérôme Cornillon, Driss Chaoui, Jean Pierre Marolleau, Lucie Obéric, Katell Le Dû, Luc‐Matthieu Fornecker, Olivier Tournilhac, (unknown), (unknown), Marie Robin, Jérôme Tamburini, Pauline Brice	7
8	Indications et résultats de la splénectomie dans les pathologies hématologiques 2017 ·Journal de Chirurgie Viscérale ·S. Bonnet, Alexis Guédon, Jean‐Antoine Ribeil, Felipe Suárez, Jérôme Tamburini, Sébastien Gaujoux	1
9	Indications and outcome of splenectomy in hematologic disease 2017 ·Journal of Visceral Surgery ·S. Bonnet, Alexis Guédon, Jean‐Antoine Ribeil, Felipe Suárez, Jérôme Tamburini, Sébastien Gaujoux	28
10	FLT3 inhibitors: clinical potential in acute myeloid leukemia 2017 ·OncoTargets and Therapy ·(unknown), Alexa S. Green, Thiago Trovati Maciel, Ivan Cruz Moura, Anskar Y.H. Leung, Didier Bouscary, Jérôme Tamburini	35
11	Polyserositis in the course of chronic myelomonocytic leukemia: impact of hypomethylating agents 2016 ·(unknown), Lise Willems, Bénédicte Deau, Sylvain Pilorge, (unknown), Patricia Franchi, (unknown), Christine Lorut, (unknown), Antoine Rabbat, N. Dupin, Marco Alifano, Didier Bouscary, Jérôme Tamburini, (unknown)	2
12	Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy 2011 ·Haematologica ·(unknown), Arnaud Jacquel, Nathalie Droin, Patrick Auberger, Didier Bouscary, Jérôme Tamburini, Marc Müller, Michaëla Fontenay, Johanna Chluba, Éric Solary	100
13	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study 2011 ·Haematologica ·François Vergez, Alexa S. Green, Jérôme Tamburini, Jean‐Emmanuel Sarry, (unknown), Pascale Cornillet‐Lefèbvre, Mélanie Pannetier, Aymeric Neyret, Nicolas Chapuis, Norbert Ifrah, F. Dreyfus, Stéphane Manenti, Cécile Demur, Éric Delabesse, C. Lacombe, (unknown), Didier Bouscary, Christian Récher, Valérie Bardet	147
14	Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia 2010 ·Clinical Cancer Research ·Nicolas Chapuis, Jérôme Tamburini, Alexa S. Green, Christine Vignon, Valérie Bardet, Aymeric Neyret, Mélanie Pannetier, Lise Willems, Sophie Park, (unknown), Sauveur-Michel Maira, Norbert Ifrah, François Dreyfus, Olivier Hérault, Catherine Lacombe, Patrick Mayeux, Didier Bouscary	128
15	IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia 2010 ·Blood ·Nicolas Chapuis, Sophie Park, Laurent Léotoing, Jérôme Tamburini, Frédèrique Verdier, Valérie Bardet, Alexa S. Green, Lise Willems, Fabrice Agou, Norbert Ifrah, François Dreyfus, Georges Bismuth, Véronique Baud, Catherine Lacombe, Patrick Mayeux, Didier Bouscary	68
16	Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody 2009 ·Haematologica ·Nicolas Chapuis, Jérôme Tamburini, Pascale Cornillet‐Lefèbvre, (unknown), Valérie Bardet, Lise Willems, Sophie Park, Alexa S. Green, Norbert Ifrah, François Dreyfus, Patrick Mayeux, C. Lacombe, Didier Bouscary	113
17	Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia 2009 ·Haematologica ·Sophie Park, Nicolas Chapuis, Jérôme Tamburini, Valérie Bardet, Pascale Cornillet‐Lefèbvre, Lise Willems, Alexa S. Green, Patrick Mayeux, C. Lacombe, Didier Bouscary	236
18	Balancing Risk Versus Benefit in the Treatment of Waldenström's Macroglobulinemia Patients with Nucleoside Analogue–Based Therapy 2009 ·Clinical Lymphoma & Myeloma ·Xavier Leleu, Jérôme Tamburini, Aldo M. Roccaro, Pierre Morel, Jacob D. Soumerai, Vincent Lévy, Mathieu Wémeau, (unknown), Stéphanie Poulain, Zachary R. Hunter, Irene M. Ghobrial, Steven P. Treon, Véronique Leblond	20
19	Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients 2007 ·Blood ·Jérôme Tamburini, Caroline Elie, Valérie Bardet, Nicolas Chapuis, Sophie Park, Philippe Broët, Pascale Cornillet‐Lefèbvre, Bruno Lioure, Valérie Ugo, Odile Blanchet, Norbert Ifrah, Francis Witz, François Dreyfus, Patrick Mayeux, Catherine Lacombe, Didier Bouscary	112
20	Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia 2007 ·American Journal of Respiratory and Critical Care Medicine ·Anne Bergeron, Delphine Réa, Vincent Lévy, C. Picard, Véronique Meignin, Jérôme Tamburini, Heriberto Bruzzoni‐Giovanelli, Fabien Calvo, Abdellatif Tazi, Philippe Rousselot	116

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact